Merck & Co. Inc.
(NYSE:MRK) shares were trading higher on Friday on a continued rally on better-than-expected third-quarter earnings and upbeat fiscal 2026 guidance. 08.
313 billion, reflecting increased contributions from new products as well as strength in Oncology and Animal Health. Read Also: Merck Discontinues Bacterial Infection Drug in Europe Analyst On Sales Timing And Price Target Increase Guggenheim raised its price forecast from $170 to $171, while maintaining its Buy rating.
Analyst Vamil Divan said sales benefited from timing of purchases by approximately $550 million, which accounts for much of the sales beat relative to expectations. Oncology Pipeline Strength And Keytruda Patent Expiry Preparation Additionally, Guggenheim sees continued confidence in the potential upside of multiple assets across their Oncology product portfolio, including sac-TMT and intismeran (INT).
Divan called Merck’s three Presidential Symposia at the European Society for Medical Oncology meeting earlier this month an impressive showing for its pipeline as it prepares for Keytruda’s upcoming loss of exclusivity. " The INTerpath-001 trial in partnership with Moderna Inc.
(NASDAQ:MRNA) delivered the first positive Phase 3 results for an individualized neoantigen therapy under development for skin cancer. S.
Food and Drug Administration accepted Sacituzumab tirumotecan (Sac-TMT) Biologics License Application under priority review, with a decision date of June 15. " Following these earnings and the recent ESMO conference, Guggenheim said it is now focused on the uptake of the recently approved Lipfendra, the design and execution of the Phase 3 CHORUS trial investigating Winrevair in CpcPH-HFpEF, and multiple important upcoming clinical data readouts.
RBC Capital also maintains Merck with a Sector Perform, but lowered the price forecast from $145 to $140. 35 on Friday.
91, according to Benzinga Pro data.
